Adverse event comparison between glucagon-like peptide-1 receptor agonists and other antiobesity medications following bariatric surgery.

Jason M SamuelsKevin D NiswenderChristianne L RoumieMatthew D SpannC Robb FlynnFei YeJoseph BlankushRebecca IrlmeierLuke M FunkMayur B Patel

Published in: Diabetes, obesity & metabolism (2024)

Our results showed that GLP-1RA AOMs were not associated with an increased risk of AEs compared to non-GLP-1RA AOMs in patients who had previously undergone bariatric surgery. Prospective studies are needed to identify the optimal timeframe for GLP-1RA initiation.

Keyphrases

bariatric surgery
rheumatoid arthritis
weight loss
disease activity
obese patients
ankylosing spondylitis
interstitial lung disease
systemic lupus erythematosus
emergency department
electronic health record